Tension-Type Headache (TTH): Chronic Pain & Management

Definition & Classification (ICHD-3 Criteria)

ICHD-3 Subtypes

• Bilateral location
• Pressing/tightening (non-pulsating) quality
• Mild-to-moderate intensity
• Not aggravated by routine physical activity
• No nausea/vomiting; no more than one of photophobia or phonophobia
• Not attributed to another disorder

Clinical Features

• Pain is bilateral, predominantly occipitonuchal, temporal, or frontal — or diffuse
• Described as dull, aching, fullness, tightness, pressure ("head in a vise")
• Gradual onset; can persist with mild fluctuations for days, weeks, months, or even years — the only headache type present throughout the day, day after day
• Unlike migraine: absent persistent throbbing, nausea, photophobia, phonophobia, or clear lateralization
• Sleep is usually undisturbed; headache returns soon after awakening
• More common in women; typically arises in middle age (unlike migraine)
• Co-morbid anxiety and depression are present in the majority of patients with protracted headaches — ~1/3 have recognizable depression (Lance & Curran)
• Migraine and CTTH frequently coexist or alternate over time

Epidemiology

• 1-year prevalence: 14–93 per 100,000 for episodic; 8.1 per 100,000 for chronic TTH
• More common in women than men, regardless of age, race, or education
• More common in Western countries and in White persons vs. African Americans
• The GBD 2023 headache study (Lancet Neurol, 2025) confirms headache disorders, including TTH, remain a leading cause of global disability

Pathophysiology

• Peripheral sensitization: Increased myofascial tenderness/pericranial tenderness, especially in CTTH (measured by laser devices showing hardened trapezius/pericranial muscles)
• Central sensitization: Chronic bombardment of dorsal horn neurons by pain impulses → neurons become autonomously overactive, maintained by excitatory amino acids (glutamate/NMDA)
• Nitric oxide (NO) hypothesis: NO creates central sensitization to sensory input from cranial structures — inhibitors of NO synthase reduce muscle hardness and pain in CTTH
• Serotonin and endorphin dysregulation: Linked to the efficacy of tricyclic antidepressants
• Surface EMG shows no persistent muscle contraction in most patients with CTTH — contradicting the original "tension" theory
• Genetic factors remain uncertain; comorbid migraine adds complexity

TTH as a Chronic Pain Problem

1. Peripheral input (e.g., myofascial tenderness, stress, neck pain) drives initial nociception
2. With chronification, dorsal horn / thalamic neurons sustain autonomous activity even after peripheral triggers resolve
3. Deafferentation pain model: structural/physiologic changes in the spinal cord produce persistent stimulation of pain pathways — explaining why simple analgesics have limited effect in severe CTTH
4. Medication overuse headache (MOH): Using analgesics >3 days/week leads to analgesic rebound and worsens headache — a critical pitfall in CTTH management

Management

Acute / Episodic Treatment

⚠️ Triptans are NOT effective in pure TTH (effective only when TTH coexists with migraine). Ergotamine and propranolol are also ineffective unless migraine features coexist.

Preventive (Prophylactic) Treatment for CTTH

Tricyclics work via serotonin/endorphin elevation + NMDA receptor inhibition in the pain pathway. Discontinue treatment after 6 months; taper by 20–25% every 2–3 days to avoid rebound.

⚠️ Botulinum toxin (onabotulinum toxin A): Multiple placebo-controlled trials in CTTH were negative — not recommended.

Non-Pharmacological Treatment

Behavioral treatments produce slower but more durable improvement — up to several years without ongoing sessions.

Prognosis

• Variable; adolescents with two or more psychiatric comorbidities (depression, anxiety) have worse prognosis
• Untreated, CTTH can persist indefinitely and severely impact quality of life
• Medication overuse headache (MOH) is a major complication — gradual withdrawal of daily analgesics, ergotamines, or triptans is essential when present
• Brain tumor risk in chronic headache patients: <1–2 in 1,000 — though fear of sinister cause commonly drives presentations

Recent Evidence Update

• Network meta-analysis (PMID 38813682, Ann Med 2024): Among simple analgesics for acute episodic TTH, ibuprofen and naproxen demonstrate superior efficacy vs. paracetamol; caffeine-combined formulations show added benefit.
• Physiotherapy meta-analysis (PMID 40129422, J Oral Facial Pain Headache 2025): Manual therapy and exercise show modest short-term benefits in CTTH, though long-term evidence remains limited — consistent with existing guideline skepticism.
• GBD 2023 (PMID 41240916, Lancet Neurol 2025): Headache disorders remain a top cause of years lived with disability globally, underscoring TTH as a major public health burden.

Psychiatric Comorbidities in Chronic Tension-Type Headache (CTTH)

Overview

1. Major Depressive Disorder (MDD) & Depressive Symptoms

• In the classic Lance & Curran series, ~one-third of patients with persistent tension headaches had readily recognizable symptoms of depression
• In clinical practice, chronic anxiety or depression of varying severity is present in the majority of patients with protracted headaches
• Depression amplifies the physiological response to pain — the two conditions mutually reinforce each other in a vicious cycle
• In a community-based study, almost 50% of adolescents with chronic daily headaches had at least one psychiatric disorder, most commonly major depression and panic disorder (Bradley and Daroff's Neurology in Clinical Practice)
• The 20–60% prevalence of depression is observed across neurological disorders including headache, chronic pain, stroke, MS, epilepsy — highlighting a shared neurobiological substrate
• Key implication: Amitriptyline showed benefit in CTTH patients even without clinical depression (Lance & Curran controlled blinded trial), suggesting biological overlap rather than a purely reactive relationship

2. Anxiety Disorders

• Anxiety (state and trait) is independently associated with CTTH beyond depression alone
• The 2022 case-control study (Romero-Godoy et al., PMID 36079022) found:
  • State anxiety: β = 12.77 (95% CI: 4.99–20.56) — strong positive association
  • Trait anxiety: β = 8.79 (95% CI: 2.29–15.30)
  • These associations held after controlling for depression and psychopharmacological use
• Panic disorder is a common comorbid anxiety disorder in chronic daily headache
• Anxiety drives sympathetic activation, muscle tension, and vigilance toward pain — all of which can perpetuate the headache cycle
• Stress and anxiety are the most commonly identified triggers for TTH episodes

3. Negative Affectivity & Emotional Dysregulation

• CTTH is associated with heightened negative state affect (β = 5.26, 95% CI: 0.88–9.64) independent of depressive disorder
• Impaired emotional regulation — including blunted cognitive reappraisal and expressive suppression — is measurable in CTTH patients
• This suggests alexithymia-spectrum features and difficulties processing emotional distress, which may somatize as persistent headache
• Negative affectivity (neuroticism) functions as a common diathesis for both CTTH and psychiatric illness

4. Somatic Symptom Disorder & Psychosomatic Presentations

• Persistent generalized headache in both adolescents and adults is commonly caused by mild depression or anxiety manifesting somatically
• A subset of patients presents with bizarre cephalic pains (e.g., clavus hystericus — sensation of a nail driven into the head) in the context of hysteria or psychosis — raising diagnostic challenges
• Key diagnostic clue: When psychiatric symptoms remit, the headache typically resolves — confirming a primary psychiatric etiology in these cases
• Pediatric presentations can include dramatic behavioral reactions (screaming, clutching head), often reflecting underlying psychiatric disorder rather than structural disease

5. Sleep Disorders

• Sleep disturbances are a major and bidirectional comorbidity:
  • Poor sleep → lowers pain threshold → precipitates or worsens TTH
  • Chronic pain → disrupts sleep architecture → worsens mood, fatigue, and pain sensitivity
• An RCT (PMID 34054116, Holistic Nursing Practice 2024) demonstrated that progressive muscle relaxation and deep breathing significantly improved pain, disability, and sleep simultaneously in CTTH patients — confirming the linked nature of these domains
• Sleep deprivation activates the hypothalamic-pituitary axis and increases inflammatory cytokines that lower pain thresholds

6. Post-Traumatic Stress Disorder (PTSD) & Trauma History

• Childhood abuse history is significantly linked to headache comorbid with depression:
  • Women with migraine/headache + major depression are twice as likely to report childhood sexual abuse
  • If abuse continued past age 12, the risk of comorbid depression was 5 times higher (Tietjen et al., 2007)
• Mass casualty event studies (e.g., Utøya attack follow-up by Gronli et al.) found increased risk of both migraine and tension-type headache, along with sleep disturbances, at 2-year follow-up — linking trauma to TTH chronification
• PTSD heightens central sensitization through hypothalamic-pituitary-adrenal (HPA) axis dysregulation and noradrenergic hyperactivity

7. Medication-Overuse Headache (MOH) & Behavioral Comorbidities

• Patients with psychiatric comorbidity are more likely to overuse analgesics — creating a vicious cycle toward MOH (analgesic use >3 days/week)
• A 2025 study (PMID 40079498, Brain & Behavior) identified psychiatric risk factors as important contributors to progression to chronic daily headache and MOH
• Addiction-related traits and impulsivity may predispose to analgesic overuse and MOH development

Neurobiological Mechanisms Linking CTTH and Psychiatric Illness

Prognostic Impact

Clinical Implications

Assessment

• Routine screening for depression (PHQ-9), anxiety (GAD-7), and sleep quality in all CTTH patients
• Ask about trauma history, medication use frequency, and emotional regulation
• Consider formal psychiatric referral when PHQ-9 ≥10 or when headache persists despite adequate treatment

Integrated Treatment Approach

Pharmacological:
  Amitriptyline 10–75 mg HS (tricyclics: superior to SSRIs in CTTH)
  ↳ Works via serotonin/endorphin ↑ + NMDA inhibition
  
Non-pharmacological:
  CBT + relaxation/biofeedback → Superior to either alone
  ↳ Addresses catastrophizing, fear-avoidance, stress reactivity
  
Sleep hygiene + sleep disorder treatment
  ↳ Breaks pain-sleep-mood vicious cycle
  
Trauma-focused therapy (if PTSD/trauma history)
  
Analgesic withdrawal (if MOH present)